FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number:              | 3235-0287 |  |  |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| Estimated average burden |           |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |  |  |

| Check this box if no longer subject to | STATEMENT OF  |
|--|---------------|
| Section 16. Form 4 or Form 5           |               |
| obligations may continue. See          |               |
| Instruction 1(b).                      | Filed pursuan |

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person <sup>*</sup><br><u>McCourt Marion</u> |  |                | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>REGENERON PHARMACEUTICALS</u> ,<br><u>INC.</u> [ REGN ] |                        | tionship of Reporting Pers<br>all applicable)<br>Director<br>Officer (give title           | ion(s) to Issuer<br>10% Owner<br>Other (specify<br>below) |
|---|--|----------------|--|------------------------|--|---|
| (Last)<br>777 OLD SAW M   | t) (First) (Middle)<br>OLD SAW MILL RIVER ROAD |                | 3. Date of Earliest Transaction (Month/Day/Year)<br>08/01/2022   |                        | below)<br>EVP Comme  | ,   |
| (Street)<br>TARRYTOWN<br>(City)   | NY<br>(State)                                  | 10591<br>(Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Indiv<br>Line)<br>X | idual or Joint/Group Filing<br>Form filed by One Repc<br>Form filed by More than<br>Person | orting Person   |

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr. |   | 4. Securities<br>Disposed Of |               |          | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|-----------------------------|---|------------------------------|---------------|----------|---|---|---|
|                                 |  |   | Code                        | v | Amount                       | (A) or<br>(D) | Price    | Transaction(s)<br>(Instr. 3 and 4)  |   |   |
| Common Stock                    | 08/01/2022                                 |   | M <sup>(1)</sup>            |   | 1,100                        | A             | \$342.93 | 20,744  | D   |   |
| Common Stock                    | 08/01/2022                                 |   | <b>S</b> <sup>(1)</sup>     |   | 1,100                        | D             | \$581.53 | 19,644  | D   |   |
| Common Stock                    |  |   |                             |   |                              |               |          | 138   | Ι   | By<br>401(k)<br>Plan  |

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

|  |          |  | (•.9.,  | <b>P</b> ,                              | • | ,   |       | ,  | ,                  |  |  |   |  |  |  |
|--|----------|--|---|---|---|---|-------|--|--------------------|--|--|---|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)<br>2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |          | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code (Instr.<br>8) |   | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3, 4<br>and 5) |       | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |          |  |   | Code                                    | v | (A)   | (D)   | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Non-<br>Qualified<br>Stock<br>Option<br>(right to<br>buy)  | \$342.93 | 08/01/2022                                 |   | <b>M</b> <sup>(1)</sup>                 |   |   | 1,100 | (2)  | 02/12/2028         | Common<br>Stock  | 1,100                                  | <b>\$</b> 0.0                                       | 1,600  | D  |  |

Explanation of Responses:

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/\*\* Marion McCourt

08/02/2022

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.